Molecular structure of Melphalan, CAS Number: 148-82-3
Melphalan (CAS 148-82-3)
See product citations (5)
Alternate Names:
Alkeran; L-Sarcolysine; Melfalan; Levofalan
Application:
Melphalan is A phenylamine derivative of mechorethamine
CAS Number:
148-82-3
Purity:
≥98%
Molecular Weight:
305.20
Molecular Formula:
C13H18Cl2N2O2
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Melphalan, also known as L-Phenylalanine mustard, is an alkylating agent with anticancer affects in vitro. Functioning as a bifunctional alkylating agent, Melphalan possesses two reactive groups that form covalent bonds with DNA, leading to DNA damage. Melphalan, a phenylamine derivative of mechlorethamine, exerts its effect by alkylating DNA through covalent bonding with the nitrogenous bases. Consequently, this bond induces DNA damage, ultimately leading to cell death. Animal models have utilized Melphalan to explore the effects of chemotherapy on cancer cells. Laboratory studies have employed Melphalan to investigate its impact on cell proliferation, cell cycle progression, apoptosis, and DNA repair pathways in cancer cells subjected to chemotherapy. Such cell lines include myeloma, ovarian cancer, and breast cancer cells.
Melphalan (CAS 148-82-3) References
- Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. | Palumbo, A., et al. 2010. Ann Hematol. 89: 803-11. PMID: 20232066
- Melphalan, alone or conjugated to an FSH-β peptide, kills murine testicular cells in vitro and transiently suppresses murine spermatogenesis in vivo. | Amory, JK., et al. 2014. Theriogenology. 82: 152-9. PMID: 24746827
- Pharmacokinetics of Melphalan After Intravitreal Injection in a Rabbit Model. | Buitrago, E., et al. 2016. J Ocul Pharmacol Ther. 32: 230-5. PMID: 26785130
- Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice. | Bouligand, J., et al. 2016. Pharm Res. 33: 1913-22. PMID: 27091031
- Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs. | Fernández, R. and Chon, E. 2018. J Vet Intern Med. 32: 1060-1069. PMID: 29566439
- Determination of melphalan in human plasma by UPLC-UV method. | Huang, L., et al. 2019. Cancer Chemother Pharmacol. 83: 905-910. PMID: 30847504
- Proteometabolomics of Melphalan Resistance in Multiple Myeloma. | Koomen, DC., et al. 2019. Methods Mol Biol. 1996: 273-296. PMID: 31127562
- Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma. | Koomen, DC., et al. 2021. J Proteome Res. 20: 3134-3149. PMID: 34014671
- Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens. | Shah, GL., et al. 2022. Clin Pharmacokinet. 61: 553-563. PMID: 34859337
- Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation. | Li, S., et al. 2022. J Clin Pharmacol. 62: 873-882. PMID: 35048362
- High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma. | Fernández-Gutiérrez, JA., et al. 2022. Hematology. 27: 449-455. PMID: 35413225
- Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation. | Dahi, PB., et al. 2022. Transplant Cell Ther. 28: 485.e1-485.e6. PMID: 35545213
- Newly Synthesized Melphalan Analogs Induce DNA Damage and Mitotic Catastrophe in Hematological Malignant Cancer Cells. | Poczta, A., et al. 2022. Int J Mol Sci. 23: PMID: 36430734
- Clinical Impact of Melphalan Pharmacokinetics on Transplantation Outcomes in Children Undergoing Hematopoietic Stem Cell Transplantation. | Maemura, R., et al. 2022. Cell Transplant. 31: 9636897221143364. PMID: 36537564
Inhibitor of:
AL, CTAGE3, GPx-8, Plasma Cell, and Y+LAT1.Activator of:
Ada, SLC7A6, and SSBP4.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Melphalan, 100 mg | sc-204799 | 100 mg | $139.00 | |||
Melphalan, 250 mg | sc-204799A | 250 mg | $242.00 |